Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.63 |
| ▸ | TK2 | O00142 | 3/20 | 0.61 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.55 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.47 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CDA | P32320 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL45507 | 1.00 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL2577629 | 1.00 | PYGM (0.63) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL16807564 | 0.89 | DNPH1 (0.52) | PYGMTK2DNPH1P2RY2MAPT | |
| SCHEMBL11443472 | 0.89 | DNPH1 (0.52) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL15798486 | 0.89 | PYGM (0.65) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL11443474 | 0.88 | PYGM (0.52) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL11443473 | 0.88 | P2RY2 (0.55) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| Xylose SCHEMBL7077042 | 0.87 | PYGM (0.50) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL1140108 | 0.87 | PYGM (0.62) | PYGMTK2DNPH1SLC28A1SLC28A2 | |
| SCHEMBL14853793 | 0.86 | DNPH1 (0.71) | PYGMTK2DNPH1SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2298 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220145295-A1 | ENZYMATIC RNA SYNTHESIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-05-12 | — | — | US | claimed |
| EP-3864151-A2 | ENZYMATIC RNA SYNTHESIS | President and Fellows of Harvard College (US) | 2021-08-18 | — | — | EP | claimed |
| CN-113195720-A | Enzymatic RNA synthesis | 哈佛大学的校长及成员们 | 2021-07-30 | — | — | CN | claimed |
| EP-3431484-A1 | A FLUORESCENT CYCLIC DINUCLEOTIDE AND ITS USE IN METHODS OF IDENTIFYING SUBSTANCES HAVING AN ABILITY TO MODULATE THE CGAS/STING PATHWAY | Ludwig-Maximilians-Universität München (DE) | 2019-01-23 | — | — | EP | claimed |
| US-20150211004-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-30 | — | — | US | claimed |
| EP-2838541-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | Agency For Science, Technology And Research (SG) | 2015-02-25 | — | — | EP | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| US-20050118605-A9 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | claimed |
| US-20050037370-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | BAKER BRENDA F (US) | 2005-02-17 | — | — | US | claimed |
| US-20050032069-A1 | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation | ISIS PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2004044245-A1 | OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE AND GUANINE AND THEIR USE IN GENE MODULATION | ISIS PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | claimed |
| EP-0763049-B1 | NUCLEOSIDE MONOPHOSPHATE DERIVATIVES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS | HEIDELBERG PHARMA HOLDING GMBH (DE) | 2003-04-02 | — | — | EP | claimed |
| US-6025343-A | Lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs | ROCHE DIAGNOSTICS GMBH (DE) | 2000-02-15 | — | — | US | claimed |
| EP-0763049-A1 | NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS | Roche Diagnostics GmbH (DE) | 1997-03-19 | — | — | EP | claimed |
| WO-1995032984-A1 | NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS | BOEHRINGER MANNHEIM GMBH (DE) | 1995-12-07 | — | — | WO | claimed |
| US-20240240187-A1 | SIRNA TARGETING TMPRSS6 FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS | SILENCE THERAPEUTICS GMBH (DE) | 2024-07-18 | — | — | US | disclosed |
| US-20240229041-A2 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF CNNM4 IN A CELL | ASOCIACIÓN CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC BIOGUNE (ES) | 2024-07-11 | — | — | US | disclosed |
| EP-0747351-A2 | Thiocationic lipids, pharmaceutical compositions and methods of use thereof | GEN-PROBE INCORPORATED (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
| WO-1995032984-A1 | NEW LIPID ESTERS OF NUCLEOSIDE MONOPHOSPHATES AND THEIR USE AS IMMUNOSUPPRESSIVE DRUGS | BOEHRINGER MANNHEIM GMBH (DE) | 1995-12-07 | — | — | WO | disclosed |